Lilly’s Lartruvo Withdrawal Stirs Questions About Payment For Accelerated Approval Drugs

 
• By Sue Sutter

News that the soft tissue sarcoma drug will come off the market after its confirmatory trial failed to verify clinical benefit spurs Memorial Sloan-Kettering’s Peter Bach to ask whether Lilly will refund money to payers.

Glowing and broken light bulb comparison concept, problem and solution, failure and success, learning from mistake
Lartruvo is coming off the market, thanks to a failed confirmatory study. • Source: Shutterstock

More from Drug Pricing

More from Scrip